Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5224568 | 0.79 | GPR119 (0.42) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL5230587 | 0.79 | USP30 (0.43) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL5228784 | 0.78 | USP30 (0.44) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL6693596 | 0.78 | DTYMK (0.40) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL5225116 | 0.78 | GPR119 (0.43) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL31735206 | 0.75 | GPR119 (0.47) | GPR119USP30POLBDTYMKGRM5 | |
| SCHEMBL5226358 | 0.74 | GRM5 (0.43) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL5226349 | 0.74 | GRM5 (0.43) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL5226196 | 0.74 | MAPK1 (0.44) | GPR119ACHEUSP30POLBDTYMK | |
| SCHEMBL5226353 | 0.74 | GRM5 (0.43) | GPR119ACHEUSP30POLBDTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001970-B1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6953791-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6951850-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6924280-B2 | Dipeptide derivatives | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-RE38524-E1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2004-06-01 | — | — | US | disclosed |
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | CARPINO PHILIP ALBERT (US) | 2004-01-15 | — | — | US | disclosed |
| US-20040006063-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030216399-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2003-11-20 | — | — | US | disclosed |
| US-6525047-B2 | Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| US-6432945-B1 | Dipeptide derivatives | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6433171-B1 | FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6429313-B2 | Dipeptide derivatives | PFIZER INC. | 2002-08-06 | — | — | US | disclosed |
| US-20020065284-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020042415-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020002165-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-01-03 | — | — | US | disclosed |
| US-20010041703-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2001-11-15 | — | — | US | disclosed |
| US-6251902-B1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | GHSR, GHRHR, GIPR | GPR119 59/4885ACHE 3514/4885USP30 2135/4885 |
| US-20020042415-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GPR119 53/4885ACHE 3808/4885USP30 1692/4885 |
| US-20010041703-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GPR119 55/4885ACHE 4103/4885USP30 1452/4885 |
| US-20020002165-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GPR119 53/4885ACHE 3808/4885USP30 1692/4885 |
| US-20040006063-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GPR119 40/4885ACHE 3741/4885USP30 1467/4885 |
| US-20030216399-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GPR119 53/4885ACHE 3808/4885USP30 1692/4885 |
| US-20020065284-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GPR119 53/4885ACHE 3808/4885USP30 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.